New York State Common Retirement Fund lessened its holdings in argenx SE (NASDAQ:ARGX – Get Rating) by 1.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 117,944 shares of the company’s stock after selling 2,327 shares during the quarter. New York State Common Retirement Fund owned 0.21% of argenx worth $44,681,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust boosted its holdings in argenx by 144.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 71 shares of the company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. KB Financial Partners LLC boosted its stake in shares of argenx by 112.5% during the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new stake in shares of argenx during the 3rd quarter worth approximately $31,000. Ronald Blue Trust Inc. boosted its stake in shares of argenx by 728.6% during the 4th quarter. Ronald Blue Trust Inc. now owns 116 shares of the company’s stock worth $41,000 after acquiring an additional 102 shares in the last quarter. Finally, Captrust Financial Advisors boosted its stake in shares of argenx by 116.7% during the 1st quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock worth $45,000 after acquiring an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 57.29% of the company’s stock.
Analyst Upgrades and Downgrades
ARGX has been the topic of several research analyst reports. SVB Leerink boosted their price target on argenx from $430.00 to $435.00 and gave the stock an “outperform” rating in a research note on Friday, March 3rd. JMP Securities boosted their price target on argenx from $443.00 to $448.00 and gave the stock a “market outperform” rating in a research note on Friday, March 3rd. Cowen boosted their price target on argenx from $441.00 to $458.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 25th. Piper Sandler boosted their price target on argenx from $465.00 to $475.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. Finally, Robert W. Baird upgraded argenx from a “neutral” rating to an “outperform” rating and set a $460.00 price objective for the company in a research report on Tuesday, March 14th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $454.64.
argenx Stock Up 1.8 %
argenx (NASDAQ:ARGX – Get Rating) last released its quarterly earnings data on Thursday, March 2nd. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($3.08) by $2.38. The business had revenue of $182.12 million during the quarter, compared to the consensus estimate of $177.11 million. argenx had a negative return on equity of 49.07% and a negative net margin of 159.36%. As a group, analysts expect that argenx SE will post -8.99 earnings per share for the current fiscal year.
About argenx
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
Further Reading
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Delta Airlines Is Ready To Fly Higher
- Global Payments Climbs After Goldman Sachs Upgrade
- Fastenal Is At A Critical Turning Point
- 3 Healthcare Stocks Insiders Are Buying
- Novo Nordisk Charges Higher and Could be Just Getting Started
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.
